[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 5 sources · 4 days · First seen · Last updated

GERD treatment expansion in Indonesia

Overview

Gastroesophageal reflux disease (GERD) prevalence is rising in Indonesia, driven by lifestyle and dietary changes. Reports indicate a general population prevalence of approximately 9.35 percent, with over half of patients in tertiary hospitals suffering from erosive esophagitis.

In response to this growing health issue, PT Daewoong Pharmaceutical Indonesia has launched fexuprazan, a potassium-competitive acid blocker (P-CAB) therapy. The product, marketed as Fexuclue 40mg, has been approved for treating erosive GERD.

Daewoong Pharmaceutical aims to capitalize on Indonesia’s growing anti-ulcer market by emphasizing the drug’s rapid acid suppression. To expand its clinical utility, the company is pursuing multi-national phase 3 clinical trials in South Korea and Indonesia to seek approval for treating gastric ulcers.

Entities

PT Daewoong Pharmaceutical Indonesia · Perkumpulan Gastroenterologi Indonesia · Indonesia · Daewoong Pharmaceutical · dr. Ari Fahrial Syam

Timeline

  1. [BUSINESS] 3 sources
    Daewoong Pharmaceutical launches Fexuclue in Indonesia

    Daewoong Pharmaceutical launched its GERD treatment Fexuclue in Indonesia, targeting a growing anti-ulcer market and expanding its presence in the Southeast Asian P-CAB sector.

  2. [HEALTH] 2 sources
    GERD prevalence rises in Indonesia as new fexuprazan therapy launches

    Indonesia sees rising GERD prevalence, with 55.4 percent of tertiary patients suffering from erosive esophagitis. PT Daewoong Pharmaceutical Indonesia has launched fexuprazan, a new P-CAB therapy.

Sources

dailymagazine.co.kr · healthmedia.co.kr · jawapos.com · medcom.id · thebionews.net